Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with Lethal influenza H1N1 virus

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Fukushi, Masaya ^a,b   Yamashita, Makoto ^c   Miyoshi Akiyama, Tohru ^a   Kubo, Shuku ^c   Yamamoto, Kenji ^a   Kudo, Koichiro ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; CARBON DIOXIDE; CHEMOKINE; CYTOKINE; LANINAMIVIR OCTANOATE; OXYGEN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD GAS ANALYSIS; CARBON DIOXIDE BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG SCREENING; FEMALE; GENERAL CONDITION; HISTOPATHOLOGY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LETHALITY; LUNG FUNCTION TEST; LUNG INJURY; LUNG WEIGHT; MONOTHERAPY; MOUSE; NONHUMAN; OXYGEN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS LOAD;

ANIMALS; BODY WEIGHT; CARBON DIOXIDE; CHEMOKINES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; ORGAN SIZE; ORTHOMYXOVIRIDAE INFECTIONS; OXYGEN; PRESSURE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; PULMONARY SURFACTANTS; SURVIVAL ANALYSIS; VIRAL LOAD; ZANAMIVIR;

MUS; ORTHOMYXOVIRIDAE;

EID: 84864754428     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042419     Document Type: Article

References (64)

1. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (2009) Dawood FS, Jain S, Finelli L, Shaw MW, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360 (25): 2605-2615.
2. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, et al. (2009) Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in mexico. N Engl J Med 361 (7): 680-689.
3. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, et al. (2010) 2009 pandemic influenza A (H1N1): Pathology and pathogenesis of 100 fatal cases in the united states. Am J Pathol 177 (1): 166-175.
4. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, et al. (2004) Avian influenza A (H5N1) in 10 patients in vietnam. N Engl J Med 350 (12): 1179-1188.
5. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, et al. (2005) Human disease from influenza A (H5N1), thailand, 2004. Emerg Infect Dis 11 (2): 201-209.
6. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, et al. (2009) H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 374 (9688): 451-458.
7. Nakajima N, Sato Y, Katano H, Hasegawa H, Kumasaka T, et al. (2012) Histopathological and immunohistochemical findings of 20 autopsy cases with 2009 H1N1 virus infection. Mod Pathol 25 (1): 1-13.
8. Ware LB, Matthay MA, (2000) The acute respiratory distress syndrome. N Engl J Med 342 (18): 1334-1349.
9. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, et al. (1994) The american-european consensus conference on ARDS. definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149 (3 Pt 1): 818-824.
10. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE, (1967) Acute respiratory distress in adults. Lancet 2 (7511): 319-323.
11. Katzenstein AL, (2006) Surgical pathology of non-neoplastic lung disease. Philadelphia: Saunders.
12. Esteban A, Fernandez-Segoviano P, Frutos-Vivar F, Aramburu JA, Najera L, et al. (2004) Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings. Ann Intern Med 141 (6): 440-445.
13. Tomashefski JF Jr, (2000) Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 21 (3): 435-466.
14. Wong SS, Yuen KY, (2006) Avian influenza virus infections in humans. Chest 129 (1): 156-168.
15. Hui DS, Lee N, Chan PK, (2010) Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest 137 (4): 916-925.
16. Peiris JS, Cheung CY, Leung CY, Nicholls JM, (2009) Innate immune responses to influenza A H5N1: Friend or foe? Trends Immunol 30 (12): 574-584.
17. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, et al. (2008) Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 105 (23): 8091-8096.
18. Yokoyama T, Tateishi K, Tsushima K, Agatsuma T, Yamamoto H, et al. (2010) A case of severe ARDS caused by novel swine-origin influenza (A/H1N1pdm) virus: A successful treatment with direct hemoperfusion with polymyxin B-immobilized fiber. J Clin Apher 25 (6): 350-353.
19. Turner DA, Rehder KJ, Peterson-Carmichael SL, Ozment CP, Al-Hegelan MS, et al. (2011) Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A. Respir Care 56 (7): 941-946.
20. Yatera K, Yamasaki K, Kawanami T, Tokuyama S, Ogoshi T, et al. (2011) A case of successful treatment with polymyxin B-immobilized fiber column direct hemoperfusion in acute respiratory distress syndrome after influenza A infection. Intern Med 50 (6): 601-605.
21. Namendys-Silva SA, Hernandez-Garay M, (2010) Hydrocortisone therapy for patients with H1N1 influenza A infection. Intensive Care Med 36 (6): 1097; author reply 1100-1.
22. Confalonieri M, Cifaldi R, Dreas L, Viviani M, Biolo M, et al. (2010) Methylprednisolone infusion for life-threatening H1N1-virus infection. Ther Adv Respir Dis 4 (4): 233-237.
23. Ottolini M, Blanco J, Porter D, Peterson L, Curtis S, et al. (2003) Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol 36 (4): 290-294.
24. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, et al. (2009) CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53 (1): 186-192.
25. Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M, (2010) Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother 54 (3): 1256-1264.
26. Yamashita M, (2010) Laninamivir and its prodrug, CS-8958: Long-acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother 21 (2): 71-84.
27. Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, et al. (2010) Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog 6 (2): e1000786.
28. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460 (7258): 1021-1025.
29. Koyama K, Takahashi M, Oitate M, Nakai N, Takakusa H, et al. (2009) CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother 53 (11): 4845-4851.
30. Koyama K, Takahashi M, Nakai N, Takakusa H, Murai T, et al. (2010) Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats. Xenobiotica 40 (3): 207-216.
31. Sugaya N, Ohashi Y, (2010) Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 54 (6): 2575-2582.
32. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, et al. (2010) Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51 (10): 1167-1175.
33. Orgeig S, Hiemstra PS, Veldhuizen EJ, Casals C, Clark HW, et al. (2010) Recent advances in alveolar biology: Evolution and function of alveolar proteins. Respir Physiol Neurobiol 173 Suppl: S43-54.
34. Baudouin SV, (2004) Exogenous surfactant replacement in ARDS-one day, someday, or never? N Engl J Med 351 (9): 853-855.
35. Hartl D, Griese M, (2006) Surfactant protein D in human lung diseases. Eur J Clin Invest 36 (6): 423-435.
36. Goerke J, (1998) Pulmonary surfactant: Functions and molecular composition. Biochim Biophys Acta 1408 (2-3): 79-89.
37. Wright JR, (2005) Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 5 (1): 58-68.
38. Whitsett JA, Weaver TE, (2002) Hydrophobic surfactant proteins in lung function and disease. N Engl J Med 347 (26): 2141-2148.
39. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, et al. (1995) Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 152 (6 Pt 1): 1860-1866.
40. Eisner MD, Parsons P, Matthay MA, Ware L, Greene K, et al. (2003) Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 58 (11): 983-988.
41. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, et al. (1999) Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 160 (6): 1843-1850.
42. Fukushi M, Ito T, Oka T, Kitazawa T, Miyoshi-Akiyama T, et al. (2011) Serial histopathological examination of the lungs of mice infected with influenza A virus PR8 strain. PLoS One 6 (6): e21207.
43. White MR, Crouch E, van Eijk M, Hartshorn M, Pemberton L, et al. (2005) Cooperative anti-influenza activities of respiratory innate immune proteins and neuraminidase inhibitor. Am J Physiol Lung Cell Mol Physiol 288 (5): L831-40.
44. Crouch E, Nikolaidis N, McCormack FX, McDonald B, Allen K, et al. (2011) Mutagenesis of surfactant protein D informed by evolution and x-ray crystallography enhances defenses against influenza A virus in vivo. J Biol Chem 286 (47): 40681-40692.
45. Rello J, Pop-Vicas A, (2009) Clinical review: Primary influenza viral pneumonia. Crit Care 13 (6): 235.
46. Kliegman RM (2007) Nelson textbook of pediatrics, 18th. edition. Elsevier.
47. Martin RJ, Fanaroff AA, Walsh MC, (2011) Fanaroff and martin's neonatal-perinatal medicine. St. Luo: Mosby. pp. 2008.
48. Thurlbeck WM (1995) Pathology of the lung. New York: Thieme.
49. Hasleton PS (1996) Spencer's pathology of the lung. New York: The McGraw-Hill Companies, Inc.
50. Iwasaki T, Tamura S, Kumasaka T, Sato Y, Hasegawa H, et al. (1999) Exacerbation of influenzavirus pneumonia by intranasal administration of surfactant in a mouse model. Arch Virol 144 (4): 675-685.
51. Hillaire ML, van Eijk M, van Trierum SE, van Riel D, Saelens X, et al. (2011) Assessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitro. PLoS One 6 (9): e25005.
52. Kingma PS, Whitsett JA, (2006) In defense of the lung: Surfactant protein A and surfactant protein D. Curr Opin Pharmacol 6 (3): 277-283.
53. Inoue T, Suzuki K, (2010) Histopathological effects of intratracheal administration of artificial lung surfactant in a model of murine paraquat lung. Kawasaki Medical Jounal 36 (4): 295-300.
54. Kesecioglu J, Beale R, Stewart TE, Findlay GP, Rouby JJ, et al. (2009) Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 180 (10): 989-994.
55. Matthay MA, Idell S, (2010) Update on acute lung injury and critical care medicine 2009. Am J Respir Crit Care Med 181 (10): 1027-1032.
56. Gunther A, Ruppert C, Schmidt R, Markart P, Grimminger F, et al. (2001) Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2 (6): 353-364.
57. Skokic F, Hudic I, Hotic N, Colic B, Praso M, et al. (2010) Surfactant replacement therapy in influenza A H1N1. Pediatr Infect Dis J 29 (4): 387.
58. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, et al. (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79 (5): 2910-2919.
59. Murata M, Otsuka M, Mizuno H, Shiratori M, Miyazaki S, et al. (2010) Development of an enzyme-linked immunosorbent assay for measurement of rat pulmonary surfactant protein D using monoclonal antibodies. Exp Lung Res 36 (8): 463-468.
60. Lucattelli M, Bartalesi B, Cavarra E, Fineschi S, Lunghi B, et al. (2005) Is neutrophil elastase the missing link between emphysema and fibrosis? evidence from two mouse models. Respir Res 6: 83.
61. Northway WH Jr, Rosan RC, Porter DY, (1967) Pulmonary disease following respirator therapy of hyaline-membrane disease. bronchopulmonary dysplasia. N Engl J Med 276 (7): 357-368.
62. Okuno Y, Matsumoto K, Isegawa Y, Ueda S, (1994) Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 68 (1): 517-520.
63. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, et al. (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56 (18): 4096-4102.
64. Safronetz D, Zivcec M, Lacasse R, Feldmann F, Rosenke R, et al. (2011) Pathogenesis and host response in syrian hamsters following intranasal infection with andes virus. PLoS Pathog 7 (12): e1002426.